Long‐Term (2‐Year) Clinical Events Following Transthoracic Intramyocardial Gene Transfer of VEGF‐2 in No‐Option Patients

Reilly, John P.; Grise, Mark A.; Fortuin, F. David; Vale, Peter R.; Schaer, Gary L.; López, John J.; Camp, Joan M. Van; Henry, Timothy D.; Richenbacher, Wayne E.; Losordo, Douglas W.; Schatz, Richard; Isner, Jeffrey M.

doi:10.1111/j.1540-8183.2005.04026.x

Cited by 67 publications

(30 citation statements)

References 12 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Again, all patients reported improvement in angina symptoms over time, and these patients also had documented collateralization and/or improved myocardial perfusion scans after therapy [204,205]. Similar results were reported by this group with intravascular delivery of the VEGF-2 gene [206,207], and this approach may have a durable benefit at 2 years [208]. The AGENT (angiogenic gene therapy trial) study has looked at the benefits of intracoronary delivery of adenoviral-FGF-4 in patients with chronic stable angina.…”

Section: Coronary Angiogenesissupporting

confidence: 75%

Cardiovascular gene delivery: The good road is awaiting☆

Brewster

Brey

Greisler

2006

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials.

show abstract

Section: Coronary Angiogenesissupporting

confidence: 75%

Cardiovascular gene delivery: The good road is awaiting☆

Brewster

Brey

Greisler

2006

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

show abstract

“…20,21 The only reported, major side effect was the occurrence of a remarkable edema of the leg, probably due to the potent permeabilizing activity of VEGF. 22 A series of over 20 clinical trials followed in the late 1990s and early 2000s, entailing the injection of naked plasmid DNA encoding VEGF to the myocardium of patients with severe coronary artery disease (CAD) not amenable to surgical revascularization either through a mini left anterior thoracotomy [23][24][25][26][27][28] or by a transendocardial approach using a NOGA catheter. 29 Even more recently, an open-label, uncontrolled Phase I trial with a VEGF-A 165 plasmid (the GENESIS I trial) was carried out in Argentina by direct intramyocardial injection in 10 patients.…”

Section: Clinical Use Of Vegfmentioning

confidence: 99%

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

2012

View full text Add to dashboard Cite

“…Current tests report that the use of high doses of VEGF, compared with low doses and placebo, improves myocardial perfusion in patients with severe angina and provides evidence of a dose-dependent positive effect [46.47]. Confronted with evidence, VEGF has been shown to be a potential angiogenic factor, which benefits in medium and long term follow-up have been or are being assessed, including the improvement of quality of life, functional class of heart failure, angina class, functional capacity and reduction of myocardial ischemia [25,28,45,46,[48][49][50][51][52][53][54][55][56][57].…”

Section: Controlled Clinical Trials Of Gene Therapymentioning

confidence: 99%

Terapia gênica para cardiopatia isquêmica

Eibel¹,

Rodrigues²,

Giusti³

et al. 2011

Rev Bras Cir Cardiovasc

View full text Add to dashboard Cite

Severe ischemic heart disease with refractory angina, occurs in increasing incidence. Alternative forms of treatment, in an attempt to reduce myocardial ischemia and relief of symptoms has been studied. In this context, gene therapy is an option, for the possibility of inducing angiogenesis, establish collateral circulation and reperfuse ischemic myocardium. Several clinical trials have been conducted and, except for specific cases of adverse effects, there is indication of safety, feasibility and potential effectiveness of therapy. The clinical benefit, however, is not yet well established. In this article we review the clinical trials of gene therapy for patients with ischemic heart disease. The approach includes: (1) myocardial ischemia and angiogenesis on the pathophysiological aspects involved, (2) growth factors, dealing with specific aspects and justifying the use in cardiac patients with no option for conventional therapy, (3) controlled clinical trials, where a summary of the main studies involving gene therapy for severe ischemic heart disease is presented, (4) our experience, especially on preliminary results of the first gene therapy clinical trial in Brazil and (5) future prospects.Keywords: Gene therapy. Myocardial ischemia. Angina pectoris. ResumoCardiopatia isquêmica grave com angina refratária a formas convencionais de tratamento apresenta-se em uma crescente incidência. Para tratar angina refratária, terapias alternativas na tentativa de redução da isquemia miocárdica e alívio de sintomas têm sido estudadas. Neste contexto, a terapia gênica representa uma opção, pela possibilidade de induzir angiogênese, estabelecer circulação colateral e reperfundir miocárdio isquêmico. Diversos ensaios clínicos têm sido conduzidos e, com exceção de casos isolados e específicos de efeitos adversos, há indicação de segurança, viabilidade e potencial eficácia da terapia. O benefício clínico não está bem definido. Neste artigo, revisamos os ensaios clínicos que utilizaram terapia gênica para tratamento de pacientes cardiopatas isquêmicos. A abordagem inclui: (1) isquemia miocárdica e angiogênese, sobre os aspectos fisiopatológicos envolvidos; (2) fatores de crescimento, tratando sobre aspectos específicos e justificando a utilização em pacientes cardiopatas isquêmicos sem opções pela terapêutica convencional; (3) ensaios clínicos controlados, onde é apresentado um resumo dos principais estudos envolvendo terapia gênica para tratamento da cardiopatia isquêmica grave; (4) nossa experiência, especialmente sobre resultados preliminares do primeiro ensaio clínico de terapia gênica do Brasil e (5) perspectivas. Descritores: Terapia de genes. Isquemia miocárdica. Angina pectoris.RBCCV 44205-1332

show abstract

Long‐Term (2‐Year) Clinical Events Following Transthoracic Intramyocardial Gene Transfer of VEGF‐2 in No‐Option Patients

Cited by 67 publications

References 12 publications

Cardiovascular gene delivery: The good road is awaiting☆

Cardiovascular gene delivery: The good road is awaiting☆

VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond

Terapia gênica para cardiopatia isquêmica

Contact Info

Product

Resources

About